Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines
Authors:
- Shailendra VermaSVShailendra Verma
- Susan DentSDSusan Dent
- Benjamin J.W. ChowBCBenjamin J.W. Chow
- Daniel RaysonDRDaniel Rayson
- Tamar SafraTSTamar Safra
- 1 August 2008
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 34 (5) , 391-406
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Role of liposomal anthracyclines in breast cancerAnnals of Oncology, 2007
- Cardiac safety of liposomal anthracyclinesCardiovascular Toxicology, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Pegylated Liposomal Doxorubicin in the Treatment of Breast CancerClinical Breast Cancer, 2003
- Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical UpdateThe Oncologist, 2003
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Cardiac Dysfunction in the Trastuzumab Clinical Trials ExperienceJournal of Clinical Oncology, 2002
- Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2Annals of Oncology, 2000
- Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.Journal of Clinical Oncology, 1997